Skip to main content
SpringerLink
Log in

Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations

  • Chapter
  • First Online:
Book cover Cardiac Considerations in Chronic Lung Disease

Part of the book series: Respiratory Medicine ((RM))

Abstract

Pulmonary hypertension (PH) is an important complication of chronic parenchymal lung diseases. The current definition of PH requires an abnormal resting mean pulmonary arterial pressure >20 mmHg during right heart catheterization (RHC). The most common chronic lung conditions that cause PH are chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), but PH can occur in the context of other parenchymal lung diseases including combined pulmonary fibrosis and emphysema (CPFE), sarcoidosis, lymphangioleiomyomatosis (LAM), and pulmonary Langerhans cell histiocytosis (PLCH). PH that occurs due to chronic lung diseases or chronic hypoxia (high altitude or severe sleep-disordered breathing) comprises Group 3 PH, whereas conditions such as sarcoidosis, LAM, and PLCH have multiple or multifactorial mechanisms and are classified into Group 5 PH.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.

    Google Scholar 

  2. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914.

    Google Scholar 

  3. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis And Treatment Of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.

    Article  PubMed  CAS  Google Scholar 

  4. Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–16.

    Article  PubMed  Google Scholar 

  5. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart And Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1–15.

    Article  PubMed  Google Scholar 

  6. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.

    Article  CAS  PubMed  Google Scholar 

  7. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371–85.

    Article  CAS  PubMed  Google Scholar 

  8. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93(3):391–8.

    Google Scholar 

  9. Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 1985;102(1):29–36.

    Article  CAS  PubMed  Google Scholar 

  10. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;131(4):493–8.

    Article  CAS  PubMed  Google Scholar 

  11. Chaouat A, Bugnet A-S, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189–94.

    Article  PubMed  Google Scholar 

  12. Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? Am J Respir Crit Care Med. 2018;198(8):1000–11.

    Article  CAS  PubMed  Google Scholar 

  13. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest. 2012;142(5):1166–74.

    Article  PubMed  Google Scholar 

  14. Girard A, Jouneau S, Chabanne C, Khouatra C, Lannes M, Traclet J, et al. Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy. Respiration. 2015;90(3):220–8.

    Google Scholar 

  15. Calcaianu G, Canuet M, Schuller A, Enache I, Chaouat A, Kessler R. Pulmonary arterial hypertension-specific drug therapy in COPD patients with severe pulmonary hypertension and mild-to-moderate airflow limitation. Respiration. 2016;91(1):9–17.

    Google Scholar 

  16. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6):1292–301.

    Article  PubMed  Google Scholar 

  17. Agostoni P, Doria E, Galli C, Tamborini G, Guazzi MD. Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;139(1):120–5.

    Article  CAS  PubMed  Google Scholar 

  18. Domenighetti GM, Saglini VG. Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease. Chest. 1992;102(3):708–14.

    Article  CAS  PubMed  Google Scholar 

  19. Kennedy TP, Michael JR, Huang CK, Kallman CH, Zahka K, Schlott W, et al. Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. A controlled double-blind study. Am Rev Respir Dis. 1984;129(4):544–51.

    CAS  PubMed  Google Scholar 

  20. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet. 1996;347(8999):436–40.

    Google Scholar 

  21. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax. 2003;58(4):289–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respir Int Rev Thorac Dis. 2010;79(5):377–82.

    CAS  Google Scholar 

  23. Boeck L, Tamm M, Grendelmeier P, Stolz D. Acute effects of aerosolized iloprost in COPD related pulmonary hypertension – a randomized controlled crossover trial. PLoS One. 2012;7(12):e52248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(3):270–8.

    Article  CAS  PubMed  Google Scholar 

  25. Rao RS, Singh S, Sharma BB, Agarwal VV, Singh V. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci. 2011;53(2):81–5.

    PubMed  Google Scholar 

  26. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012;9(3):268–75.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Blanco I, Santos S, Gea J, Güell R, Torres F, Gimeno-Santos E, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013;42(4):982–92.

    Article  CAS  PubMed  Google Scholar 

  28. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014;2(4):293–300.

    Article  CAS  PubMed  Google Scholar 

  29. Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial. J Heart Lung Transplant. 2017;36(2):166–74.

    Article  PubMed  Google Scholar 

  30. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619–28.

    Article  CAS  PubMed  Google Scholar 

  31. Valerio G, Bracciale P, Grazia D’Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3(1):15–21.

    Article  PubMed  Google Scholar 

  32. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.

    Article  CAS  PubMed  Google Scholar 

  33. Archer SL, Mike D, Crow J, Long W, Weir EK. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest. 1996;109(3):750–5.

    Article  CAS  PubMed  Google Scholar 

  34. Jones K, Higenbottam T, Wallwork J. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest. 1989;96(4):784–9.

    Article  CAS  PubMed  Google Scholar 

  35. Ghofrani HA, Staehler G, Grünig E, Halank M, Mitrovic V, Unger S, et al. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ. 2015;5(2):296–304.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39(1):125–32.

    Article  CAS  PubMed  Google Scholar 

  37. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–52.

    Article  PubMed  Google Scholar 

  38. Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136(3):772–8.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Ghigna MR, Mooi WJ, Grünberg K. Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia: number 1 in the series “pathology for the clinician” edited by Peter Dorfmüller and Alberto Cavazza. Eur Respir Rev. 2017;26(144):170003.

    Google Scholar 

  40. Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, et al. Pulmonary hypertension in patients with chronic Fibrosing idiopathic interstitial pneumonias. PLoS One. 2015;10(12):e0141911.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev. 2017;26(145):170056.

    Google Scholar 

  42. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412–23.

    Article  PubMed  Google Scholar 

  43. Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, et al. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS One. 2018;13(5):e0197112.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011;63(8):2456–64.

    Article  PubMed  Google Scholar 

  45. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75–81.

    Article  CAS  PubMed  Google Scholar 

  46. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92–9.

    Article  PubMed  Google Scholar 

  47. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641–9.

    Article  PubMed  Google Scholar 

  48. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J, MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42(6):1622–32.

    Article  CAS  PubMed  Google Scholar 

  49. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–8.

    Article  Google Scholar 

  50. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013;143(6):1699–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014;190(2):208–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.

    Article  PubMed  Google Scholar 

  53. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J. 2015;46(5):1370–7.

    Article  PubMed  CAS  Google Scholar 

  54. Krowka MJ, Ahmad S, de Andrade JA, Frost A, Glassberg MK, Lancaster LH, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis. Chest. 2007;132(4):633A.

    Article  Google Scholar 

  55. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gómez-Marín O. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung. 2010;188(2):115–23.

    Article  CAS  PubMed  Google Scholar 

  56. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010;62(7):2101–8.

    CAS  PubMed  Google Scholar 

  57. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895–900.

    Google Scholar 

  58. Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, et al. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax. 2014;69(2):123–9.

    Article  PubMed  Google Scholar 

  59. Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013;41(4):853–60.

    Article  PubMed  Google Scholar 

  60. Nathan S, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez F, et al. RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. Eur Respir J. 2017;50(suppl 61):OA1985.

    Google Scholar 

  61. Weatherald J, Savale L, Humbert M. Medical Management of Pulmonary Hypertension with unclear and/or multifactorial mechanisms (group 5): is there a role for pulmonary arterial hypertension medications? Curr Hypertens Rep. 2017;19(11):86.

    Article  PubMed  Google Scholar 

  62. Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti J-P, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61(1):68–74.

    Article  CAS  PubMed  Google Scholar 

  63. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078–85.

    Article  PubMed  Google Scholar 

  64. Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017;50(4):1700465.

    Google Scholar 

  65. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145(4):810–7.

    Article  CAS  PubMed  Google Scholar 

  66. Barnett CF, Bonura EJ, Nathan SD, Ahmad S, Shlobin OA, Osei K, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009;135(6):1455–61.

    Article  PubMed  Google Scholar 

  67. Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015;148(4):1055–62.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Seferian A, Steriade A, Jaïs X, Planché O, Savale L, Parent F, et al. Pulmonary hypertension complicating Fibrosing Mediastinitis. Medicine (Baltimore). 2015;94(44):e1800.

    Article  Google Scholar 

  69. Condado JF, Babaliaros V, Henry TS, Kaebnick B, Kim D, Staton GW. Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):281–7.

    PubMed  Google Scholar 

  70. Fartoukh M, Humbert M, Capron F, Maître S, Parent F, Le Gall C, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161(1):216–23.

    Article  CAS  PubMed  Google Scholar 

  71. Lazor R, Etienne-Mastroianni B, Khouatra C, Tazi A, Cottin V, Cordier J-F. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax. 2009;64(3):274–5.

    Article  CAS  PubMed  Google Scholar 

  72. Lorillon G, Bergeron A, Detourmignies L, Jouneau S, Wallaert B, Frija J, et al. Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med. 2012;186(9):930–2.

    Article  PubMed  Google Scholar 

  73. Le Pavec J, Lorillon G, Jaïs X, Tcherakian C, Feuillet S, Dorfmüller P, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest. 2012;142(5):1150–7.

    Article  PubMed  Google Scholar 

  74. McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: Lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194(6):748–61.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Cottin V, Harari S, Humbert M, Mal H, Dorfmüller P, Jaïs X, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J. 2012;40(3):630–40.

    Article  PubMed  Google Scholar 

  76. Reynaud-Gaubert M, Mornex J-F, Mal H, Treilhaud M, Dromer C, Quétant S, et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation. 2008;86(4):515–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Calgary, Department of Medicine, Division of Respiratory Medicine, Calgary, AB, Canada

    Jason Weatherald

  2. Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada

    Jason Weatherald

  3. Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France

    David Montani & Olivier Sitbon

  4. Service de Pneumologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France

    David Montani & Olivier Sitbon

  5. INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France

    David Montani & Olivier Sitbon

Authors
  1. Jason Weatherald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Montani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Sitbon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason Weatherald .

Editor information

Editors and Affiliations

  1. Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

    Surya P. Bhatt

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Weatherald, J., Montani, D., Sitbon, O. (2020). Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. In: Bhatt, S. (eds) Cardiac Considerations in Chronic Lung Disease. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-43435-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-43435-9_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-43434-2

  • Online ISBN: 978-3-030-43435-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation